uniQure Management
Management criteria checks 1/4
uniQure's CEO is Matt Kapusta, appointed in Dec 2016, has a tenure of 7.33 years. total yearly compensation is $5.63M, comprised of 10.8% salary and 89.2% bonuses, including company stock and options. directly owns 0.66% of the company’s shares, worth $1.53M. The average tenure of the management team and the board of directors is 1.7 years and 7.2 years respectively.
Key information
Matt Kapusta
Chief executive officer
US$5.6m
Total compensation
| CEO salary percentage | 10.8% |
| CEO tenure | 7.3yrs |
| CEO ownership | 0.7% |
| Management average tenure | 1.7yrs |
| Board average tenure | 7.2yrs |
Recent management updates
Recent updates
Earnings Update: uniQure N.V. (NASDAQ:QURE) Just Reported And Analysts Are Trimming Their Forecasts
Mar 03
uniQure: The Valuation Got More Attractive
Feb 01Little Excitement Around uniQure N.V.'s (NASDAQ:QURE) Revenues As Shares Take 29% Pounding
Jan 17A Look At The Fair Value Of uniQure N.V. (NASDAQ:QURE)
Dec 15Revenue Downgrade: Here's What Analysts Forecast For uniQure N.V. (NASDAQ:QURE)
Aug 27Analysts Are More Bearish On uniQure N.V. (NASDAQ:QURE) Than They Used To Be
Aug 06Here's Why uniQure (NASDAQ:QURE) Can Manage Its Debt Despite Losing Money
Aug 02uniQure N.V. (NASDAQ:QURE) Looks Inexpensive After Falling 43% But Perhaps Not Attractive Enough
Jul 02Analyst Forecasts For uniQure N.V. (NASDAQ:QURE) Are Surging Higher
Jun 28uniQure N.V. (NASDAQ:QURE) Analysts Are Reducing Their Forecasts For This Year
May 14Is uniQure (NASDAQ:QURE) Using Debt Sensibly?
Apr 11News Flash: 15 Analysts Think uniQure N.V. (NASDAQ:QURE) Earnings Are Under Threat
Mar 01Does uniQure (NASDAQ:QURE) Have A Healthy Balance Sheet?
Dec 09uniQure: Clinical Risk, A Critical Upcoming Catalyst And A Cash Cushion
Sep 21uniQure N.V.: 2 Possible Regulatory Approvals Makes This A Must Watch
Aug 30uniQure N.V. (NASDAQ:QURE) Analysts Are Reducing Their Forecasts For This Year
Aug 14uniQure plunges 27% on Q2 revenue miss, postpones higher dose trial of Huntington’s disease therapy
Aug 08These 4 Measures Indicate That uniQure (NASDAQ:QURE) Is Using Debt Safely
Jun 08uniQure N.V. (NASDAQ:QURE) Analysts Are Reducing Their Forecasts For This Year
May 04uniQure N.V.: Worth A Look Based On Hemophilia B Marketing Applications
Apr 08We Think That There Are Issues Underlying uniQure's (NASDAQ:QURE) Earnings
Mar 04The Consensus EPS Estimates For uniQure N.V. (NASDAQ:QURE) Just Fell Dramatically
Feb 27Is uniQure (NASDAQ:QURE) A Risky Investment?
Feb 23uniQure: Betting On Hemophilia-B Cure
Jan 18UniQure: Leading Gene Therapy Company
Nov 06These 4 Measures Indicate That uniQure (NASDAQ:QURE) Is Using Debt Safely
Oct 24How We Are Playing UniQure
Oct 04Is uniQure N.V. (NASDAQ:QURE) Trading At A 48% Discount?
Sep 19CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | -US$308m |
| Sep 30 2023 | n/a | n/a | -US$228m |
| Jun 30 2023 | n/a | n/a | -US$187m |
| Mar 31 2023 | n/a | n/a | -US$157m |
| Dec 31 2022 | US$6m | US$609k | -US$127m |
| Sep 30 2022 | n/a | n/a | -US$125m |
| Jun 30 2022 | n/a | n/a | -US$114m |
| Mar 31 2022 | n/a | n/a | US$324m |
| Dec 31 2021 | US$5m | US$583k | US$330m |
| Sep 30 2021 | n/a | n/a | US$321m |
| Jun 30 2021 | n/a | n/a | US$303m |
| Mar 31 2021 | n/a | n/a | -US$139m |
| Dec 31 2020 | US$4m | US$585k | -US$125m |
| Sep 30 2020 | n/a | n/a | -US$166m |
| Jun 30 2020 | n/a | n/a | -US$136m |
| Mar 31 2020 | n/a | n/a | -US$124m |
| Dec 31 2019 | US$4m | US$548k | -US$124m |
| Sep 30 2019 | n/a | n/a | -US$105m |
| Jun 30 2019 | n/a | n/a | -US$103m |
| Mar 31 2019 | n/a | n/a | -US$92m |
| Dec 31 2018 | US$3m | US$502k | -US$83m |
| Sep 30 2018 | n/a | n/a | -US$90m |
| Jun 30 2018 | n/a | n/a | -US$78m |
| Mar 31 2018 | n/a | n/a | -US$78m |
| Dec 31 2017 | US$4m | US$468k | -US$79m |
Compensation vs Market: Matt's total compensation ($USD5.63M) is above average for companies of similar size in the US market ($USD1.60M).
Compensation vs Earnings: Matt's compensation has increased whilst the company is unprofitable.
CEO
Matt Kapusta (51 yo)
7.3yrs
Tenure
US$5,628,174
Compensation
Mr. Matthew Craig Kapusta, also known as Matt, served as Independent Director at Decibel Therapeutics, Inc. since March 2023 until September 25, 2023. He has been the Chief Executive Officer of uniQure N.V...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Executive Director | 7.3yrs | US$5.63m | 0.66% $ 1.5m | |
| CFO, Principal Financial Officer & GM of Amsterdam Site | 2.8yrs | US$2.13m | 0.15% $ 358.0k | |
| Chief Operating Officer | 2.9yrs | US$2.37m | 0.17% $ 408.9k | |
| Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany | no data | no data | no data | |
| Chief Business & Scientific Officer | less than a year | no data | no data | |
| Chief Legal & Compliance Officer | less than a year | no data | no data | |
| Business Development Director | 15.8yrs | no data | no data | |
| Interim Chief People and Culture Officer | less than a year | no data | no data | |
| Chief Corporate Affairs Officer | 2.1yrs | US$1.22m | no data | |
| Chief Quality Officer | 1.3yrs | no data | no data | |
| Chief Medical Officer | less than a year | no data | no data | |
| Vice President of Global Medical Affairs | no data | no data | no data |
1.7yrs
Average Tenure
53yo
Average Age
Experienced Management: QURE's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Executive Director | 9.3yrs | US$5.63m | 0.66% $ 1.5m | |
| Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany | 9.7yrs | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Non-Executive Director | 7.8yrs | US$368.42k | 0.052% $ 122.5k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Non-Executive Director | 6.6yrs | US$357.05k | 0.036% $ 83.3k | |
| Independent Non-Executive Director | 6.6yrs | US$369.55k | 0.036% $ 83.3k | |
| Independent Chairman of the Board | 5.8yrs | US$390.68k | 0.025% $ 58.7k | |
| Independent Non-Executive Director | 10.8yrs | US$355.68k | 0.028% $ 66.1k | |
| Non-Executive Director | 5.5yrs | US$350.68k | 0.078% $ 182.4k |
7.2yrs
Average Tenure
61yo
Average Age
Experienced Board: QURE's board of directors are considered experienced (7.2 years average tenure).